Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 21


Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YC, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.

Oncotarget. 2016 Feb 26. doi: 10.18632/oncotarget.7739. [Epub ahead of print]


Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.


AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.

Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL.

Clin Cancer Res. 2015 Jun 1;21(11):2601-12. doi: 10.1158/1078-0432.CCR-14-2648. Epub 2015 Mar 12.


Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature.

Lukas RV, Mata-Machado NA, Nicholas MK, Salgia R, Antic T, Villaflor VM.

Dis Esophagus. 2015 Nov-Dec;28(8):772-81. doi: 10.1111/dote.12276. Epub 2014 Aug 21.


Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.


O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer.

Hasina R, Surati M, Kawada I, Arif Q, Carey GB, Kanteti R, Husain AN, Ferguson MK, Vokes EE, Villaflor VM, Salgia R.

J Carcinog. 2013 Oct 28;12:20. doi: 10.4103/1477-3163.120632. eCollection 2013.


Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Villaflor VM, Salgia R.

J Carcinog. 2013 Mar 18;12:7. doi: 10.4103/1477-3163.109253. Print 2013.


Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB.

J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19.


Multidisciplinary approach for patients with esophageal cancer.

Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG.

World J Gastroenterol. 2012 Dec 14;18(46):6737-46. doi: 10.3748/wjg.v18.i46.6737. Review.


Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.

Hasina R, Mollberg N, Kawada I, Mutreja K, Kanade G, Yala S, Surati M, Liu R, Li X, Zhou Y, Ferguson BD, Nallasura V, Cohen KS, Hyjek E, Mueller J, Kanteti R, El Hashani E, Kane D, Shimada Y, Lingen MW, Husain AN, Posner MC, Waxman I, Villaflor VM, Ferguson MK, Varticovski L, Vokes EE, Gill P, Salgia R.

Cancer Res. 2013 Jan 1;73(1):184-94. doi: 10.1158/0008-5472.CAN-12-0915. Epub 2012 Oct 24. Erratum in: Cancer Res. 2013 Jul 15;73(14):4594.


Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer.

Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK.

J Thorac Oncol. 2012 Feb;7(2):376-81. doi: 10.1097/JTO.0b013e31824166a5.


Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease.

Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR.

Cancer. 2012 Jun 1;118(11):2962-70. doi: 10.1002/cncr.26611. Epub 2011 Oct 21.


Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.

Pederson AW, Salama JK, Haraf DJ, Witt ME, Stenson KM, Portugal L, Seiwert T, Villaflor VM, Cohen EE, Vokes EE, Blair EA.

Head Neck Oncol. 2011 Jul 26;3:31. doi: 10.1186/1758-3284-3-31.


Should esophageal resections for cancer be performed in high-volume centers only?

Feo CV, Villaflor VM, Patti MG.

Updates Surg. 2011 Sep;63(3):147-50. doi: 10.1007/s13304-011-0090-7. Epub 2011 Jun 22. Review.


Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.

Choe KS, Haraf DJ, Solanki A, Cohen EE, Seiwert TY, Stenson KM, Blair EA, Portugal L, Villaflor VM, Witt ME, Vokes EE, Salama JK.

Cancer. 2011 Oct 15;117(20):4671-8. doi: 10.1002/cncr.26084. Epub 2011 Jun 13.


Takotsubo cardiomyopathy in a patient with squamous cell esophageal carcinoma.

Schweizer MT, Mehta R, Salgia R, Villaflor VM.

J Clin Oncol. 2011 Jul 10;29(20):e598-600. doi: 10.1200/JCO.2011.35.1791. Epub 2011 Apr 25. No abstract available.


Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.

Villaflor VM, Haraf D, Salama JK, Kocherginsky M, Langerman A, Gomez-Abuin G, Beniwal P, Blair EA, Stenson KM, Portugal L, Seiwert T, Williams RD, Dekker AJ, Witt ME, Vokes EE, Cohen EE.

Ann Oncol. 2011 Nov;22(11):2501-7. doi: 10.1093/annonc/mdq785. Epub 2011 Mar 8.


Neoadjuvant treatment of esophageal cancer.

Campbell NP, Villaflor VM.

World J Gastroenterol. 2010 Aug 14;16(30):3793-803. Review.


Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.

Lilenbaum R, Villaflor VM, Langer C, O'Byrne K, O'Brien M, Ross HJ, Socinski M, Oldham FB, Sandilac L, Singer JW, Bonomi P.

J Thorac Oncol. 2009 Jul;4(7):869-74. doi: 10.1097/JTO.0b013e3181a9a020.


The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.

Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J 4th, Buckingham L, Kaiser K, Basu S, Bonomi P.

Clin Cancer Res. 2008 Apr 1;14(7):2088-94. doi: 10.1158/1078-0432.CCR-07-4013.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk